Curis, Inc. Stock price

Equities

CRIS

US2312693094

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
10.87 USD +7.73% Intraday chart for Curis, Inc. +5.23% -14.75%
Sales 2024 * 8.35M Sales 2025 * 8.74M Capitalization 64.07M
Net income 2024 * -49M Net income 2025 * -55M EV / Sales 2024 * 7.67 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 7.33 x
P/E ratio 2024 *
-1.79 x
P/E ratio 2025 *
-2 x
Employees 49
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day+7.73%
1 week+5.23%
Current month+6.67%
1 month+8.59%
3 months-22.91%
6 months+26.25%
Current year-14.75%
More quotes
1 week
10.02
Extreme 10.02
11.07
1 month
9.70
Extreme 9.7
11.07
Current year
8.24
Extreme 8.24
14.57
1 year
3.80
Extreme 3.8
20.00
3 years
3.80
Extreme 3.8
348.00
5 years
3.80
Extreme 3.8
348.00
10 years
3.80
Extreme 3.8
375.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 16-03-28
Director of Finance/CFO 52 22-07-25
Chief Tech/Sci/R&D Officer - 22-01-02
Members of the board TitleAgeSince
Director/Board Member 71 03-10-31
Chairman 82 00-02-13
Chief Executive Officer 57 16-03-28
More insiders
Date Price Change Volume
24-03-27 10.87 +7.73% 40,199
24-03-26 10.09 -6.83% 24,780
24-03-25 10.83 +0.28% 7,421
24-03-22 10.8 -0.28% 16,055
24-03-21 10.83 +4.84% 15,201

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Emavusertib, its lead clinical-stage drug candidate, is an orally available small molecule drug candidate that is designed to inhibit the Interlukin-1 receptor associated kinase 4 (IRAK4) kinase, which is an important transducer of toll-like receptor or certain interleukin receptor signaling pathways. Erivedge is an orally bioavailable small molecule, which is designed to selectively inhibit the Hedgehog signaling pathway by targeting a protein called Smoothened. Its other programs include CI-8993, Fimepinostat, CA-170 and CA-327. CI-8993 is a human IgG1 kappa monoclonal antibody directed against the VISTA protein. CA-170 is an oral small molecule drug candidate that is designed to selectively target VISTA and PDL1 immune checkpoint proteins. The Company conducts its research and development programs both internally and through strategic collaborations.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
10.87 USD
Average target price
93 USD
Spread / Average Target
+755.57%
Consensus
  1. Stock
  2. Equities
  3. Stock Curis, Inc. - Nasdaq